Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Mobocertinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Takeda announces voluntary withdrawal of lung cancer therapy
    Takeda announces voluntary withdrawal of lung cancer therapy

    03 Oct 2023

    // HEALTH ET

    https://health.economictimes.indiatimes.com/news/pharma/takeda-announces-voluntary-withdrawal-of-lung-cancer-therapy/104118437

    HEALTH ET
    03 Oct 2023
    Share Share
    Takeda Provides Update on EXKIVITY® (mobocertinib)
    Takeda Provides Update on EXKIVITY® (mobocertinib)

    02 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231002169446/en

    BUSINESSWIRE
    02 Oct 2023
    Share Share
    Takeda's Exkivity, a rival to J&J, fails in lung cancer trial
    Takeda's Exkivity, a rival to J&J, fails in lung cancer trial

    01 Aug 2023

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/pharma/takedas-exkivity-sputters-lung-cancer-trial-accelerated-approval-and-jj-rivalry-line

    Angus Liu FIERCE PHARMA
    01 Aug 2023
    Share Share
    FoundationOne®Liquid CDx Receives FDA-Approval as a Companion for EXKIVITY
    FoundationOne®Liquid CDx Receives FDA-Approval as a Companion for EXKIVITY

    04 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230504005202/en

    BUSINESSWIRE
    04 May 2023
    Share Share
    Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China
    Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China

    11 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230111005569/en

    BUSINESSWIRE
    11 Jan 2023
    Share Share
    NHS grants fast-track access to Takeda's lung cancer drug Exkivity
    NHS grants fast-track access to Takeda's lung cancer drug Exkivity

    22 Mar 2022

    // K. Dunleavy PHARMAPHORUM

    https://pharmaphorum.com/news/nhs-grants-fast-track-access-to-takedas-lung-cancer-drug-exkivity/

    K. Dunleavy PHARMAPHORUM
    22 Mar 2022
    Share Share